|Bid||131.37 x 800|
|Ask||132.01 x 800|
|Day's Range||130.80 - 132.13|
|52 Week Range||121.00 - 148.99|
|Beta (3Y Monthly)||0.72|
|PE Ratio (TTM)||21.80|
|Earnings Date||Oct 15, 2019|
|Forward Dividend & Yield||3.80 (2.91%)|
|1y Target Est||149.35|
Glaxo (GSK) seeks approval for its anemia candidate, daprodustat, in Japan. Moreover, once every two months administration of cabotegravir and rilpivirine shows non-inferiority to once a month administration in HIV patients in a clinical study.
Johnson & Johnson (NYSE:JNJ) is about to trade ex-dividend in the next 3 days. This means that investors who purchase...
The greenback has been in rally mode since late June, and now the U.S. Dollar Index is approaching multi-year highs. The strong dollar will create winners and losers. Which stocks are likely to suffer a negative impact from the strong dollar?
Endo International and Allergan could avoid going to trial in a landmark case out of Ohio accusing pharmaceutical companies of marketing practices that preceded the opioid epidemic.
An Oklahoma judge will rule on Monday on whether Johnson & Johnson should be held liable in a lawsuit by the state's attorney general who argues the drugmaker should be forced to pay $17 billion for fueling the opioid epidemic. Judge Thad Balkman in Norman, Oklahoma, will deliver his decision from the bench after presiding over the first trial to result from thousands of lawsuits by state and local governments against opioid manufacturers and distributors, the court said. Opioids were involved in almost 400,000 overdose deaths from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention.
With the markets still digesting the events of last week, multiple companies are riding choppy waters. However, few names have as many question marks as Johnson & Johnson (NYSE:JNJ) stock. A household staple and an American icon, Johnson & Johnson has suffered from severe scandals. Even though JNJ stock has calmed down in recent sessions, investors rightfully remain skeptical about JNJ.Source: Sundry Photography / Shutterstock.com Obviously, the company's most pressing controversy is its asbestos-contamination scandal. In December 2018, the company lost a motion "to reverse a jury verdict that awarded $4.69 billion to women who blamed their ovarian cancer on asbestos in the company's baby powder and other talc products," according to The New York Times. Immediately, the devastating news cratered Johnson & Johnson stock.Worse yet, the company's PR crisis was only beginning. According to court documents, Johnson & Johnson had known for decades that its talc-based products were possibly contaminated with asbestos. However, management decided to keep that information from leaking to the public. Naturally, the image of one of America's most trusted brands turning on their customers badly hurt JNJ stock.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Marijuana Stocks to Ride High on the Farm Bill However, JNJ stock has stabilized in recent weeks.Still, the weight of the asbestos scandal has loomed over JNJ stock. Several lawsuits related to the matter still could impose meaningful liabilities on Johnson & Johnson stock. Furthermore, the diversified pharmaceutical giant must deal with a trial in Oklahoma. The state alleges that JNJ played a significant role in America's widespread opioid crisis.Can Johnson & Johnson stock finally catch a break? A Dark Cloud Hangs Over JNJ StockConsidering how terrible these controversies are, it's tempting to say that Johnson & Johnson stock offers no redeemable value. It's not just the scandal itself, which again is horrific, shameful, and perhaps unforgivable; additionally, the company's good reputation has evaporated almost instantaneously.Back in 2015, Interbrand recognized Johnson & Johnson as one of the world's top brands. At that time, the brand consultancy firm declared that the company "evokes some of the most cherished childhood experiences." That was one of many reasons to buy JNJ stock: another was that the company enjoyed multiple, non-cyclical revenue channels.But over the past year or so, the organization has nuked its family-friendly image. Now, when people see Johnson & Johnson, they see the worst thing possible: an innocent person dying of cancer.If that wasn't enough, the owners of Johnson & Johnson stock will face a dark cloud that permeates throughout the brand. According to the Harvard Business Review, corporate scandals have a long shelf life.For instance, automaker Volkswagen was beset by a massive controversy several years ago. In order to meet government emissions regulations, it essentially hacked monitoring components to produce falsified data. The scandal took a very long time to recover from, and it is still negatively affecting the company's reputation.And in VW's case, only emissions stats were involved. In JNJ's scandal, people died. Undoubtedly, the scandal will prevent many people from touching JNJ stock. Johnson & Johnson Stock Is Only Compelling for SpeculatorsFor conservative investors, the most reasonable action is readily apparent: they should not jump into JNJ stock.As I mentioned above, the asbestos scandal is both atrocious and extensive. Moreover, in many cases, it takes companies a long time to recover from controversies. Also, you should realize that there are other diversified pharmaceutical firms that don't have the baggage of Johnson & Johnson stock.But if you're a risk-tolerant speculator, JNJ stock might have some attraction for you. First, scandals don't always result in indefinite doom. For a prime example, look at Equifax (NYSE:EFX). Although the credit-monitoring agency compromised millions of Americans' private data, EFX stock eventually recovered. In fact, EFX is one of the top-performing equities of 2019.Second, JNJ stock has done well from a technical standpoint, despite the obvious headwinds it's facing. It may not hit all-time highs anytime soon. However, the shares are still riding a long-term bullish trend channel, which is quite surprising, given the scandal's grievous nature.As a cautionary note, I must stress that JNJ stock is not for the faint of heart. However, its steep discount provides an attractive entry point into the shares of this solid (other than its scandal) and relevant company.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Marijuana Stocks to Ride High on the Farm Bill * 8 Biotech Stocks to Watch After the Q2 Earnings Season * 7 Unusual, Growth-Oriented REITs to Buy for Your Portfolio The post Johnson & Johnson Stock Is a Gamble, but an Interesting One appeared first on InvestorPlace.
Even under normal circumstances, the healthcare stocks are prone to headline risk. Case in point, what happened to Sarepta (NASDAQ:SRPT) last night when the stock fell 15% on FDA news. Add to it that the U.S. is approaching another round of elections, and it makes healthcare stocks even riskier than normal -- through no fault of their own.In late June, I discussed three healthcare stocks to buy and for the most part the trades paid quickly. But since then, the stock markets in general had several mini corrections. We had fear flashes over geopolitical headlines, China's currency crisis and most recently, a bond-yield crash. So it's only fair to revisit those names again as the dust is settling. * 10 Undervalued Stocks With Breakout Potential So today we are discussing United Health (NYSE:UNH), Pfizer (NYSE:PFE), and Johnson & Johnson (NYSE:JNJ) stocks. I'll start with my conclusion first. All three are still good stocks to buy at these levels -- but for different reasons.InvestorPlace - Stock Market News, Stock Advice & Trading Tips Johnson & Johnson (JNJ)Johnson & Johnson is a long-time American success story. They are a global household name and their products are ubiquitous. From a valuation perspective, JNJ stock is relatively cheap because it has a modest price-to-earnings (P/E) ratio and pays a decent dividend.JNJ could be cheaper, but this is a management team that has proven itself through thousands of headline worries. The current headlines are nothing new for JNJ. So they have nothing but a temporary effect on the overall trajectory of JNJ stock.That said, Johnson & Johnson is still a buy here for anyone who's looking to add this sector to their portfolio. It is important to note that the company is probably past its talcum-powder headline risk by now even though it's not officially resolved. So I wouldn't take a full position all at once. Alternatively, I can sell puts below the current JNJ stock price to generate income from the intrinsic value of JNJ stock this way I don't even need a rally to win. United Health (UNH)United Health stock has performed the best of the three healthcare stocks since my last write up. It had an immediate 9% spike so from a trading perspective that was good timing.In addition, the overall thesis on UNH stock since then has not changed. It is still trailing the S&P 500 year-to-date. But over the last five years, UNH stock is up 180%, which is four times better than the S&P.After the July spike, UNH stock price faded the rally, but is has fallen into the same support zone from which it broke out. So this is the opportunity for the bulls to rinse-and-repeat another run.Technically speaking, UNH range is tightening into a point, so a move is coming in either direction. It is setting lower-highs and higher-lows at a point that coincides with the 12 month point-of- control for the stock. This is significant because this is literally where bulls and bears have agreed the most.So they will fight it out hard at this price once more and create support. As long as UNH stock holds above $240 per share, the bulls have a shot at retesting $260 or higher. There will be resistance along the way perhaps at $255 and most certainly at $256.50. * 10 Mid-Cap Dividend Stocks to Buy Now Conversely, there is the threat that the bears are able to break below $240 per share. If that happens, it could turn into a bearish head-and-shoulder pattern to target $224 per share. This is not a forecast but it's definitely a scenario that exists currently below UNH stock price. Pfizer (PFE)Pfizer stock was once bulletproof, but it can't even find footing of late. But maybe this time will be different. From current levels Pfizer stock can mount a revenge rally. Clearly so far, its stock performance metrics are poor so this has a lot of hopium tied to it.So this is definitely a tactical trade, and it should have a hard stop below $34 per share. This inadvertently is also a long-term five-year-old pivot point that also happens to be the point of control for that same period. So mathematically speaking, this is where bulls and bears love to disagree. This congestion should act as support.Simply put, if I buy PFE stock here, I literally have more upside potential than downside risk based on the 5-year price history. Fundamentally speaking, PFE is not expensive selling at 17 P/E and three times book. Yes, it can get cheaper, but this trade set up is tactical, so fundamentals don't matter as much for the short term.Longer-term, the Pfizer management team needs to re-earn Wall Street trust so that trades like this one would be with conviction. Maybe then the bulls will be able to drag the PFE stock out of the dumps and back in line with the overall stock market or at least its sector.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. Join his live chat room for free here. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Dividend Stocks to Load Up On * The 10 Biggest Losers from Q2 Earnings * 5 Dependable Dividend Stocks to Buy The post 3 Healthcare Stocks to Trade: UNH, JNJ and PFE appeared first on InvestorPlace.
Health Canada has granted biopharmaceutical researcher and cannabis producer Avicanna Inc (TSX: AVCN) with a research license that will allow the company to perform research and intellectual property development on cannabinoids at its facility in the MaRS Discovery District in Toronto. It's a cannabis license, but for research and pharmaceutical development," CEO Aras Azadian told Benzinga in an interview.
The Zacks Analyst Blog Highlights: Berkshire Hathaway, Johnson & Johnson, NVIDIA, Booking and Fidelity
The St. Pete manufacturer was also issued a positive outlook on its new $1.8 billion commercial paper program.
These three defensive consumer stocks can add stability to your portfolio. These stocks deal with staples and are less susceptible to market volatility.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Johnson & Johnson (“J&J”) (JNJ). The Company has been embroiled in significant litigation by over 11,000 consumers claiming that its iconic talc powder products contained asbestos that caused cancer. Some cases have resulted in massive verdicts against J&J including a $117 million award by one New Jersey jury in April 2018 and a $4.7 billion award in Missouri to 22 plaintiffs in July 2018.
Moody's Investors Service ("Moody's") assigned a Prime-3 short term rating to Jabil Inc.'s ("Jabil") new $1.8 billion commercial paper program. Borrowings under the new commercial paper program will be used to replace current revolver borrowings.
[Editor's note: "10 Best Stocks to Buy and Hold Forever" was previously published in July 2019. It has since been updated to include the most relevant information available.]In a market environment that overwhelmingly encourages constant activity by investors who seemingly want to double their money every week, a discussion of stocks to buy and hold forever seems comically out of place.And yet, for better or worse, that's the mindset all of us should adopt when deploying most of our investing capital. More often than not, the more you trade, the worse you end up doing.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt has been said (and verified) that 95% of true "day traders" -- the most aggressive and active of all market participants -- end up losing money by being too active for their own good. Conversely, the fact that Warren Buffett's favorite holding period is "forever" and how he's got a track record most investors would envy is just as telling. * 10 Cheap Dividend Stocks to Load Up On With that as the backdrop, here's a rundown of 10 stocks to buy and hold forever … or at least until something significant changes with your life plans or the companies themselves. AT&T (T)Dividend Yield: 5.% Year-to-date gain: 20%Calling a spade a spade, shares of telecom giant AT&T Inc. (NYSE:T) haven't been easy to own in a while. The stock is down from its mid-2016 peak, while most other stocks are well up for the timeframe.Source: Shutterstock The impasse has been an increasingly-tougher wireless and broadband market. But now that it's acquired media outfit Time Warner Inc (NYSE:TWX), a turnaround might have begun.If your intended timeframe really is "forever" though, a tough couple of years is nothing … particularly considering you're collecting a healthy dividend yield on your position's current value.More than that though, this is a telco name with a lot of clout, and a little more than $50 billion in the bank. Alphabet (GOOGL, GOOG)Dividend Yield: N/A Year-to-date gain: 12.7%Fans and followers of the company will likely know that Google parent company Alphabet Inc (NASDAQ:GOOGL, NASDAQ:GOOG) beat Q4's earnings estimate, posting $12.77 per share.Source: Shutterstock What got lost in the shuffle is how operating margins fell to 21 % from last quarter's 24%.Appreciated or not, Alphabet is a profit and revenue growth machine that has earned its spot on a list of "forever" stocks to buy. It may not always beat estimates, but it does always increase its numbers. * 10 Cheap Dividend Stocks to Load Up On That's because it keeps finding a way to serve as the middleman for about 70% of web searches done on desktops, and boasts being the preferred search engine for about 90% of the queries made via a mobile device.If it was going to be toppled, we'd see evidence of it by now. 3M (MMM)Dividend Yield: 3.67% Year-to-date gain: -18%In an era where complicated companies are shedding disparate parts of themselves so each arm can be hyper-focused on doing one thing exceedingly well, 3M Co (NYSE:MMM) is something of an outlier.Source: Shutterstock It offers everything from office supplies to healthcare products to the power transformers you see perched on top of power-line poles.It's wild mix that seems to work for 3M though, giving the company something to sell regardless of the economic environment.The clincher: 3M has managed to pay and increase its dividend every year going all the way back to 1977. Walmart (WMT)Dividend Yield: 1.88% Year-to-date gain: 21%Yes, the advent of Amazon.com, Inc. (NASDAQ:AMZN) has proven problematic for the world's biggest retailer, Walmart Inc (NYSE:WMT).Source: Shutterstock Rumors of Walmart's death at the hands of Amazon, however, have been greatly exaggerated.After being knocked over a few years ago, the company has regrouped, having figured out a way to fight the ever-growing reach of its online rival. The evidence? Last quarter's revenue, excluding currency fluctuations, jumped 2.9%. * 10 Cheap Dividend Stocks to Load Up On While it has been an ugly battle at times, Walmart has finally learned how to compete with Amazon.com. The fact that it can leverage its stores to do so only bolsters the bullish case. Southern Co (SO)Dividend Yield: 4.49% Year-to-date gain: 30%No list of stocks to buy and hold forever would be complete without a utility stock. In good times and bad, consumers almost always pay their electricity bill.Source: Shutterstock And, even though margins are thin and power providers don't have a ton of pricing power, they have little competition in most markets. Most requests for rate hikes are also approved without question.To that end, Southern Co (NYSE:SO) is one of the top picks of the litter.Southern serves nine million customers, mostly in the south, although it's represented in most of the major regions of the United States. More important, Southern Co has dished out stunningly consistent (even if tiny) profit growth, setting the stage for equally consistent dividends. It has not failed to increase its annual payout since the late 90's. Johnson & Johnson (JNJ)Dividend Yield: 2.9% Year-to-date gain: 1.15%As advanced as we've become as a society, the need for medicines, surgical products and simple healthcare solutions like Band-Aids and Tylenol is never going to go away.Source: Shutterstock That means Johnson & Johnson (NYSE:JNJ) -- which maintains a bigger product portfolio than most investors realize -- will always have something to sell to someone.That being said, don't think for a minute that a play on J&J is capitulation in the search for respectable growth. The company isn't just about treating tummy troubles and selling no-tears baby shampoo. * 10 Cheap Dividend Stocks to Load Up On It still operates a pharmaceutical arm as well, with its pharma operational revenue jumping 4.4% year-over-year last quarter, Berkshire Hathaway (BRK.B, BRK.A)Dividend Yield: N/A Year-to-date gain: -2%If the Warren Buffett mindset is the underlying philosophy in play here, why not go straight to the source and buy a piece of the fund he built from the ground up? That's Berkshire Hathaway Inc. (NYSE:BRK.B, NYSE:BRK.A).Source: Shutterstock Sure, in his most recent letter to shareholders, the Oracle of Omaha said he's struggling to find new companies at a "sensible purchase price," which is the life-blood of the organization's growth. There's also the stark reality that the 87-year-old Buffett is increasingly less involved with Berkshire Hathaway. That separation is only going to widen as time marches on.Still, he has more than proven his way works for the long haul. Over the course of the past half-century, Berkshire stock has performed about twice as well as the S&P 500 has. Waste Management (WM)Dividend Yield: 1.73% Year-to-date gain: 33%There's an old adage … the only two sure things in life are death and taxes.Source: Shutterstock It's a humorous point about the limited nature of human life and the far-reaching power of the IRS. But, it's not necessarily a complete cliche. There's a third certainty. That is, as long as people are living on the planet earth, they'll be creating garbage to shuttle to their nearby landfill. Some of the best stocks to buy and hold are companies that haul that garbage away.Enter Waste Management, Inc. (NYSE:WM), which runs garbage-pickup services for 21 million North American customers. Although its top and bottom lines ebb and flow, the bigger trend for both is pointed upward. * 10 Cheap Dividend Stocks to Load Up On Look for more of the same too. As CEO Jim Fish pointed out last year, "The babyboomers are coming into a period of heavy medical spend. All of our parents are aging and spending more on medical spend. There is medical waste generated from that, we are in that business. The industrial economy is important to us.Whether it's through repatriation from the new tax law, or just through the fact the U.S. and Canada are great places to do business and the industrial economy is showing some signs of life, we are a big industrial player on the back-end of the cycle." American Water Works (AWK)Dividend Yield: 1.61% Year-to-date gain: 37.4%Perhaps just as certain as death, taxes and the creation of trash, as long as people are alive they're going to need water to survive. That puts a water utility name like American Water Works Company Inc (NYSE:AWK) in the catbird seat. Reliability and demand make water utilities safe stocks to buy when others seem sketchy.Source: Shutterstock Much like electricity providers Southern Company, American Water Works Company -- which offers water and sewer services to 15 million people in the United States -- is rarely told no when it wants to raise rates.Water service prices have risen at above-inflation rates for the past several years, and American Water Works Company has benefited from that industry-wide trend. It's not apt to change anytime soon. Colgate-Palmolive (CL)Dividend Yield: 2.40% Year-to-date gain: 21%Last but not least, while the purchase of things like cars are cyclical, and the automobile industry itself is subject to constant reinvention, there are some consumer goods people just buy over and over again without a second thought. When it comes to the best stocks to buy and hold, you just can't forget consumer staples.Source: Shutterstock Among those often-repurchased items are Colgate toothpaste, Palmolive dish soap, Speed Stick deodorant and Cuddly fabric conditioner.Yep, they're all made by Colgate-Palmolive Company (NYSE:CL), though they're only a small sampling of the brands you'll find under the company's umbrella. * 10 Cheap Dividend Stocks to Load Up On Those who know the Colgate-Palmolive story well will know the company has gotten into some sloppy spending habits, crimping margins more than most shareholders would like. That's starting to change, however, with a serious and rather impressive cost-cutting initiative. The benefits of that work could last years, if not decades.As of this writing, James Brumley hold a long position in AT&T. You can follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 Stocks to Buy for June * 7 Stocks to Buy From One of America's Best Pension Funds * 4 Consumer Staples Stocks for Both Income and Growth The post 10 Best Stocks to Buy and Hold Forever appeared first on InvestorPlace.